Journey Medical (NASDAQ:DERM) Shares Down 5.3% – Should You Sell?

Journey Medical Co. (NASDAQ:DERM) shares dropped 5.3% during mid-day trading on Tuesday . The company traded as low as $3.99 and last traded at $4.11. Approximately 40,497 shares traded hands during trading, a decline of 20% from the average daily volume of 50,699 shares. The stock had previously closed at $4.34.

Journey Medical Trading Down 2.7 %

The business’s 50-day moving average price is $5.04 and its 200 day moving average price is $5.24. The firm has a market capitalization of $83.56 million, a price-to-earnings ratio of -4.26 and a beta of 1.00. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03.

Hedge Funds Weigh In On Journey Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TMD Wealth Management LLC purchased a new stake in shares of Journey Medical during the second quarter worth about $65,000. PVG Asset Management Corp acquired a new stake in Journey Medical during the 2nd quarter valued at approximately $894,000. ORG Wealth Partners LLC purchased a new stake in Journey Medical during the 3rd quarter worth approximately $110,000. Nwam LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at approximately $59,000. Finally, Kovitz Investment Group Partners LLC purchased a new position in shares of Journey Medical during the 3rd quarter valued at approximately $66,000. 7.25% of the stock is owned by hedge funds and other institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.